GlassScriptPhysician profile
Marc Edward Usrey
NPI 1952504045
$5,799.64
in general payments reported to CMS, 2019-2025
57 companies · $2,301 in 2025
The $2,301 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.77 · 2020: $37.92 · 2021: $124 · 2022: $194 · 2023: $1,137 · 2024: $1,971 · 2025: $2,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,108 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,108.33 |
| Education | $300.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $606.05 | 2023-2025 | Venclexta |
| Myriad Genetic Laboratories, INC. | $528.95 | 2021-2024 | Myrisk |
| Astrazeneca Pharmaceuticals LP | $336.74 | 2020-2025 | Imjudo, Imfinzi, Lynparza |
| Tempus Ai, INC | $316.40 | 2024-2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $270.70 | 2021-2025 | |
| Genentech USA, INC. | $253.20 | 2019-2025 | Polivy, Phesgo, Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $244.51 | 2023 | Imbruvica, Epkinly |
| Pfizer INC. | $239.20 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $230.79 | 2023-2025 | |
| Janssen Biotech, INC. | $202.03 | 2021-2025 | Erleada, Balversa, Talvey |
| Lilly USA, LLC | $190.06 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Aveo Pharmaceuticals, INC. | $158.01 | 2023-2025 | Fotivda |
| Array Biopharma INC | $137.78 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| E.R. Squibb & Sons, L.L.C. | $131.63 | 2021-2025 | Opdivo |
| Dendreon Pharmaceuticals LLC | $117.95 | 2024-2025 | Provenge |
Show all 55 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Usrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.